Keap-1 Polyclonal Antibody

disease:Defects in KEAP1 may be a cause of breast cancer.,disease:Defects in KEAP1 may be involved in non small cell lung carcinomas (NSCLC) and lung adenocarcinoma.,domain:The Kelch repeats mediate interaction with NF2L2/NRF2, BPTF and PGAM5.,enzyme regulation:Ubiquitination and subsequent degradation of PGAM5 is inhibited by oxidative stress and sulforaphane.,function:Retains NFE2L2/NRF2 in the cytosol. Functions as substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1. Targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. May also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome.,PTM:Ubiquitinated and subject to proteasomal degradation.,similarity:Contains 1 BACK (BTB/Kelch associated) domain.,similarity:Contains 1 BTB (POZ) domain.,similarity:Contains 6 Kelch repeats.,subcellular location:Shuttles between cytoplasm and nucleus.,subunit:Homodimer. Interacts with the N-terminal regulatory domain of NF2L2/NRF2. Interacts with BPTF and PTMA. Interacts with CUL3. Part of a complex that contains KEAP1, CUL3 and RBX1. Interacts with PGAM5.,tissue specificity:Broadly expressed, with highest levels in skeletal muscle.,